Research programme: GlyTag fusion proteins - GlyTag

Drug Profile

Research programme: GlyTag fusion proteins - GlyTag

Alternative Names: GlyB4; GlyTags

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlyTag LLC; Wayne State University School of Medicine
  • Class Recombinant fusion proteins
  • Mechanism of Action Epidermal growth factor inhibitors; Epidermal growth factor receptor antagonists; Intercellular signalling peptide and protein inhibitors; Intercellular signalling peptide and protein stimulants; Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Breast cancer; Neurological disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Breast-cancer in USA (Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neurological-disorders in USA (Injection)
  • 17 Feb 2005 This programme is available for licensing worldwide (http://www.glytag.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top